A systematic review on imaging-guided metastasis directed therapy for oligorecurrent prostate cancer: revolution or devolution?
CONCLUSIONS: MDT is highly appealing given its potential to delay disease progression and adverse events of systemic therapy. Nonetheless, data remains immature to recommend MDT on a large scale and the selection criteria for patients have yet been defined. Today, MDT should be administered within a clinical trial and results of future research are eagerly awaited.
PMID: 32083417 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Prostate Cancer | Study | Urology & Nephrology